Combining<unk>  with strong inhibitors of the liver enzyme CYP3A4, such as ketoconazole, significantly increases its concentrations in the blood plasma and its area under the curve (AUC). Less potent CYP3A4 inhibitors such as diltiazem have a less pronounced effect on this parameters, which is not considered clinically significant. Inhibitors and inducers of the enzyme UGT2B7, alcohol dehydrogenases, and aldehyde dehydrogenases, as well as the transporter P-glycoprotein (P-gp), may also influence<unk>  concentrations in the body. Digoxin, which is transported by P-gp, is not affected by<unk> ; this means that<unk>  does not significantly inhibit or induce P-gp. No relevant interactions with antihypertensive drugs or with PDE5 inhibitors have been found in studies; although combination with other α1-antagonists is not well studied.
Silodosin
Terazosin
Erythrocrine
Doxazosin
Tamsulosin
Oxymetazoline
Methylergometrine
Tropicamide